| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
BIRC3 induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shu-Liang Li, Pei-Yao Wang, Yang-Pu Jia, Zhao-Xiong Zhang, Hao-Yu He, Peng-Yu Chen, Xin Liu, Bang Liu, Li Lu and Wei-Hua Fu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Tianjin Municipal Education Commission Scientific Research Project |
No. 2018KJ055 |
|
| Corresponding Author |
Wei-Hua Fu, MD, PhD, Professor, Surgeon, Teacher, Department of General Surgery, Tianjin Medical University General Hospital, Tianjin Medical University, No. 154 Anshan Road, Tianjin 300052, China. tjmughgs_fwh@163.com |
| Key Words |
Gastric cancer; Human epidermal growth factor receptor 2; Trastuzumab; Drug-resistance; BIRC3 |
| Core Tip |
Our study discovered that the overexpression of BIRC3 leads to the stimulation of phosphoinositide 3-kinase-Akt phosphorylation and activation. Consequently, this enhances the proliferation of human epidermal growth factor receptor 2-positive tumor cells and inhibits apoptosis, resulting in resistance to trastuzumab. |
| Publish Date |
2024-10-25 10:27 |
| Citation |
<p>Li SL, Wang PY, Jia YP, Zhang ZX, He HY, Chen PY, Liu X, Liu B, Lu L, Fu WH. BIRC3 induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer. <i>World J Gastrointest Oncol</i> 2024; 16(11): 4436-4455</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i11/4436.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i11.4436 |
